766TiP - CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent

R De Wit,K Fizazi,E Efstathiou,R Dittamore,S Hitier,K Pantel,C Sternberg,B Tombal,C Wülfing,J De Bono

doi:10.1093/annonc/mdw372.50

766TiP - CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent

R De Wit, K Fizazi + Show 8 more

Open Access

https://doi.org/10.1093/annonc/mdw372.50

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2016
License type: publisher-specific-oa

Affiliation: Erasmus MC, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Epic Sciences (United States), Sanofi (France), University Medical Center Hamburg-Eppendorf, Universität Hamburg, Carlo Forlanini Hospital, Cliniques Universitaires Saint-Luc, Asklepios Klinik Altona

#Agent In Men #Metastatic Castration-resistant Prostate Cancer + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

766TiP - CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent

Full Text